Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S.
Chatterjee S, et al. Among authors: hill eg.
Clin Cancer Res. 2019 Feb 1;25(3):1036-1049. doi: 10.1158/1078-0432.CCR-18-0706. Epub 2018 Oct 16.
Clin Cancer Res. 2019.
PMID: 30327305
Free PMC article.